Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease
暂无分享,去创建一个
[1] Xiaojing Sui,et al. Cerebrospinal fluid biomarkers of Alzheimer’s disease , 2014, Neuroscience Bulletin.
[2] A. Kurz,et al. The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: predicting the outcome , 2013, European Archives of Psychiatry and Clinical Neuroscience.
[3] F. Jessen,et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease , 2012, Neurology.
[4] C. Jack,et al. Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.
[5] R. Honea,et al. Alzheimer disease biomarkers are associated with body mass index , 2011, Neurology.
[6] K. Rufibach,et al. Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome* , 2011, Molecular & Cellular Proteomics.
[7] R. Hamilton,et al. Diversity and Disparity in Dementia: The Impact of Ethnoracial Differences in Alzheimer Disease , 2011, Alzheimer disease and associated disorders.
[8] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[9] Chengjie Xiong,et al. Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.
[10] J. Provias,et al. Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. , 2011, Current Alzheimer research.
[11] Robert A. Dean,et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.
[12] K. Blennow,et al. Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease , 2011, Dementia and Geriatric Cognitive Disorders Extra.
[13] P. Calabresi,et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. , 2011, Journal of Alzheimer's Disease.
[14] S. Potkin,et al. Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort , 2010, Neurology.
[15] J. Storch,et al. Tissue-specific Functions in the Fatty Acid-binding Protein Family* , 2010, The Journal of Biological Chemistry.
[16] Murray Grossman,et al. Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease , 2010, Acta Neuropathologica.
[17] K. Eguchi,et al. Development of an Ultra-Rapid Diagnostic Method Based on Heart-Type Fatty Acid Binding Protein Levels in the CSF of CJD Patients , 2010, Cellular and Molecular Neurobiology.
[18] C. Jack,et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.
[19] Dolores Catelan,et al. Multiple testing in disease mapping and descriptive epidemiology. , 2010, Geospatial health.
[20] Murray Grossman,et al. Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.
[21] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[22] D. Martins‐de‐Souza. Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? , 2010, European Archives of Psychiatry and Clinical Neuroscience.
[23] Madhav Thambisetty,et al. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. , 2010, Biomarkers in medicine.
[24] Reinhard Schliebs,et al. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and β-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain , 2009, International Journal of Developmental Neuroscience.
[25] P. Carmeliet,et al. Role and therapeutic potential of VEGF in the nervous system. , 2009, Physiological reviews.
[26] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[27] E. Umlauf,et al. The role of proteomics in dementia and Alzheimer’s disease , 2009, Acta Neuropathologica.
[28] Jing Zhang,et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.
[29] P. Lewczuk,et al. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. , 2008, Methods.
[30] J. Wiltfang,et al. Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies , 2007, Neurodegenerative Diseases.
[31] H. Hinterhuber,et al. Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.
[32] F. Spener,et al. Release of brain–type and heart–type fatty acid–binding proteins in serum after acute ischaemic stroke , 2005, Journal of Neurology.
[33] G. Román. Vascular dementia. Advances in nosology, diagnosis, treatment and prevention. , 2004, Panminerva medica.
[34] P. Lewczuk,et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases , 2004, Neuroscience Letters.
[35] A. Twijnstra,et al. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. , 2004, Clinical chemistry.
[36] Yong Song Gho,et al. Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer’s disease , 2004, Neurobiology of Aging.
[37] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] Anders Wallin,et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia , 2002, Neurobiology of Aging.
[39] J. Veerkamp,et al. Fatty acid-binding proteins of nervous tissue , 2001, Journal of Molecular Neuroscience.
[40] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[41] B. Thies,et al. Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. , 1999 .
[42] J. LaManna,et al. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.
[43] Giovanni B. Frisoni,et al. Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .
[44] J. Morris,et al. Validation of clinical diagnostic criteria for Alzheimer's disease , 1988, Annals of neurology.
[45] P. Lescuyer,et al. Heart-Fatty Acid-Binding Protein as a Marker for Early Detection of Acute Myocardial Infarction and Stroke , 2012, Molecular Diagnosis.
[46] K. Blennow,et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.
[47] N. Stocchetti,et al. Increased levels of CSF heart-type fatty acid-binding protein and tau protein after aneurysmal subarachnoid hemorrhage. , 2008, Acta neurochirurgica. Supplement.
[48] Werner Zolg,et al. The Proteomic Search for Diagnostic Biomarkers IN TRANSLATION , 2006 .
[49] G. Lubec,et al. Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's disease. , 2003, Journal of neural transmission. Supplementum.
[50] Nancy Reagan,et al. Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .
[51] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .